DNA Link and Amplicon Express have entered an agreement to develop genomic services.

Under the agreement, Amplicon Express will be responsible to extract high molecular weight DNA samples from bacteria, plants, animals and humans, while DNA Link will use the samples to develop a library for PacBio sequencing for genome analysis.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The agreement enables the two partners to further develop nucleic acid extraction process, library preparation and PacBio sequencing.

Proteomics International Laboratories plans to enter an agreement with Linear Clinical Research to develop an advanced analytical testing and clinical trials package.

The two partners will jointly work to expand their presence in the biopharmaceutical and oncology markets.

"The agreement enables the two partners to offer end-to-end testing and clinical trial services to their clients."

The agreement enables the two partners to offer end-to-end testing and clinical trial services to their clients.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Kamada and Yissum Research Development Company of Hebrew University of Jerusalem have entered an agreement to develop recombinant human Alpha 1 Antitrypsin.

The agreement enables the partners to increase the protein yields and functionality.

Neovacs has announced to acquire interferon alpha (IFNa) manufacturing technology from Amega Biotech.

The acquisition enables Neovacs to further advance the clinical development and commercialisation strategy of IFNalpha Kinoid vaccine to treat lupus.

Pfizer plans to raise gross proceeds of $1.75bn through the public offering of 3% notes due 2026.

Citigroup Global Markets, Credits Suisse Securities (USA), Merrill Lynch, Pierce, Fenner & Smith, and RBC Capital Markets are acting as joint book running managers for the offering.

The company plans to use the funds to purchase tender notes and for general corporate purposes.

Image: Pfizer plans to raise gross proceeds of $1.75bn through the public offering of 3% notes. Photo: courtesy of Kultur Enis via Wikipedia.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact